Global Health Matters
Evidence shows that progress made in sharing IP through voluntary agreements, combined with tiered-pricing and not-for-profit arrangements for low- and middle-income countries has led to production of COVID-19 therapeutics exceeding demand for all disease severity levels and in all patient settings. Efforts must now focus on ensuring these products reach ...
Read More
This blog was originally published on Health Awareness on 3 October 2022. Through public and private sector partnerships, a global initiative innovates for better access to cancer care worldwide. The global prevalence of cancer is increasing rapidly, presenting an especially heavy burden for people in low and middle-income countries (LMICs). ...
Read More
Viruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose. The biopharmaceutical industry is proud to ...
Read More
This article was originally published by Re:solve Global Health on 14 July 2022. The task of taking quality care to those living with cancer grows more difficult with the exploding number of new cases. A new initiative pools together expertise to widen access to timely and effective treatment. The global ...
Read More
This blog was originally published on Business & Industry on 29 June 2022. In the wake of COVID-19, lower-resourced settings need sustainable healthcare more than ever to build back better. Promising solutions are at hand. Each year, 41 million people die from heart disease, cancer, diabetes and chronic respiratory diseases[1]. ...
Read More
This blog was originally published on Health Awareness on 21 June 2022. We must take pandemic preparedness farther, faster by ensuring a joint response to future outbreaks. Our efforts against COVID-19 have surfaced critical learnings, including the need to establish a global foundational capability, fit for purpose ahead of the ...
Read More
This blog was originally published on Health Awareness on 21 June 2022. The challenge is not getting hold of COVID-19 vaccines, it is getting vaccines into arms. The healthcare community is continuing to showcase the value of vaccines throughout one’s life course. Over the last two years, the global healthcare ...
Read More
This article featured in the Media Planet Clinical Trials campaign, available online and disseminated in print with the New Scientist. The COVID-19 pandemic has taught us a lot and yet we can still keep learning. While the pandemic has impacted everyone globally in ways that could never have been imagined, ...
Read More
Vaccines are one of the most effective and cost-efficient medical technologies ever developed. Except for clean water, nothing has had a larger effect on global health than vaccines, especially for children.[1] Before COVID-19, even if vaccines saved millions of lives every year, they had become a routine and unremarkable part ...
Read More
This op-ed was originally published for Media Planet's Malaria and Neglected Tropical Diseases campaign on 25 April 2022. We must make up ground lost in the fight against malaria during the COVID-19 pandemic. Innovation in vaccines and treatment offer hope for solutions. From 2019 to 2020, there was a 12.4% ...
Read More
This article was originally published on Africa Young Innovators for Health Award on 29 March 2022. Marie-Chantal Umunyana joins IFPMA and HYPER‘s virtual discussion on: “The Importance of Diversity & Equal Opportunities in a Healthy R&D Environment – Workplace & Organizational Culture.” The discussion convened both young and senior leaders to identify and present initiatives ...
Read More
It’s been over two years since the biopharmaceutical industry committed to playing the greatest possible role in the global response to COVID-19 In that time, we have seen how one virus can disrupt all our lives, our daily routines, our education and health systems, our economies, and our world. We ...
Read More
This blog was originally published in The Medicine Maker. Technology transfer partnerships have been the cornerstone in the fight against the COVID-19 pandemic, enabling rapid scaling of health innovations but also raising new challenges. Now, we need long-term, sustainable national policies to ensure tech transfer continues to improve access to ...
Read More
This article was originally published on Pharma Boardroom on 2 March 2022. As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, ...
Read More
This piece appeared first on PharmaBoardroom. Drawing on the findings of a recent report launched under the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some of ...
Read More